Medicus Pharma Ltd 6-K, filed Dec 26, 2024
Medicus Pharma Ltd. (MDCX)
About this 6-K
Medicus Pharma Ltd filed this 6-K on December 26, 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of December 2024.
Commission File Number 001-42408
MEDICUS PHARMA LTD.
(Translation of registrant's name into English)
Suite 3400, 100 King St W
Toronto, Ontario, Canada, M5X 1A4
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INDEX TO EXHIBITS
| Exhibit | Description | |
| 99.1 | Notice of Change of Auditor | |
| 99.2 | Letter of Former Auditor | |
| 99.3 | Letter of Successor Auditor |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
Medicus Pharma Ltd. |
|
|
|
|
|
Date: December 26, 2024 |
By: |
/s/ Raza Bokhari |
|
|
|
Name: Dr. Raza Bokhari |
|
|
|
Title: Executive Chairman and Chief Executive Officer |
Exhibit 99.1
NOTICE OF CHANGE OF AUDITOR
| TO: | EisnerAmper LLP |
| MNP LLP | |
| AND TO: | Ontario Securities Commission Alberta Securities Commission British Columbia Securities Commission The Manitoba Securities Commission |
| Financial and Consumer Affairs Authority of Saskatchewan Financial and Consumer Services Commission (New Brunswick) |
|
| Nova Scotia Securities Commission | |
| Government of Newfoundland and Labrador, Office of the Superintendent Prince Edward Island Securities Office |
|
| Autorité des marchés financiers | |
| Government of Nunavut Office of the Superintendent of Securities | |
| Government of the Northwest Territories, Office of the Superintendent of Securities Office of the Superintendent of Securities, Government of Yukon |
Medicus Pharma Ltd. (the "Corporation") hereby provides notice pursuant to Section 4.11 of National Instrument 51-102 of the resignation of MNP LLP (the "Former Auditor") as the auditor of the Corporation and the appointment EisnerAmper LLP (the "Successor Auditor") in its place.
The Corporation confirms that:
1. On its own initiative, the Former Auditor tendered its resignation as auditor of the Corporation effective December 19, 2024.
2. The resignation of the Former Auditor has been approved by the audit committee and the board of directors of the Corporation.
3. The appointment of the Successor Auditor has been approved by the audit committee and the board of directors of the Corporation, effective December 19, 2024.
4. There are no reservations or modified opinions in the Former Auditor's reports for the Corporation's financial statements for the "relevant period" (as defined in NI 51-102).
5. There have been no "reportable events" as defined in Section 4.11 of National Instrument 51-102.
DATED as of the 23rd day of December, 2024.
| MEDICUS PHARMA LTD. | ||
| Per: | (signed) "Raza Bokhari" | |
| Raza Bokhari | ||
| Chief Executive Officer | ||
Exhibit 99.2
December 23, 2024
Ontario Securities Commission
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Manitoba Securities Commission
New Brunswick Financial and Consumer Services Commission
Nova Scotia Securities Commission
Prince Edward Island Office of the Superintendent of Securities
Securities NL, Government of Newfoundland and Labrador
Dear Sirs/Mesdames:
Re: Medicus Pharma Ltd. - Change of Auditor
Pursuant to National Instrument 51-102 - Continuous Disclosure Obligations, we have reviewed the information contained in the Notice of Change of Auditor of Medicus Pharma Limited dated December 19, 2024 (the "Notice") and, based on our knowledge of such information at this time:
1. We agree with paragraphs 1, 4 and 5 of the Notice.
2. With respect to paragraph 2 and 3 of the Notice, we have no basis on which to agree or disagree.
Yours very truly,
Chartered Professional Accountants
Mississauga, Ontario
 |
 |
| SUITE 800, 1600 CARLING AVENUE, OTTAWA ON, K1Z 1G3 T: 613.691.4200 F: 613.726.9009 MNP.ca |
Exhibit 99.3
 |
EisnerAmper LLP One Logan Square 130 North 18th Street, Suite 3000 Philadelphia, PA 19103 T 215.881.8800 F 215.881.8801 www.eisneramper.com |
December 23, 2024
British Columbia Securities Commission
Alberta Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Ontario Securities Commission
Financial and Consumer Services Commission - New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities - Prince Edward Island
Office of the Superintendent of Securities - Service Newfoundland and Labrador
|
Re: |
Medicus Pharma Limited |
|
|
Change of Auditor Notice dated December 23, 2024 |
|
|
|
Pursuant to National Instrument 51-102 (Part 4.11), we have read the above-noted Change of Auditor Notice and confirm our agreement with the information contained in the Notice pertaining to our firm.
Yours sincerely,
EisnerAmper LLP
Philadelphia, Pennsylvania
"EisnerAmper" is the brand name under which EisnerAmper LLP and Eisner Advisory Group LLC and its subsidiary entities provide professional services. EisnerAmper LLP and Eisner Advisory Group LLC are independently owned firms that practice in an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations and professional standards. EisnerAmper LLP is a licensed CPA firm that provides attest services, and Eisner Advisory Group LLC and its subsidiary entities provide tax and business consulting services. Eisner Advisory Group LLC and its subsidiary entities are not licensed CPA firms.